Three doses of HepB-CpG vaccine elicited more-durable seroprotective responses than two doses of that vaccine or three doses of HepB-alum vaccine.
A randomized trial called BEe-HIVe previously showed that a cytosine phosphoguanine-adjuvanted hepatitis B vaccine (HepB-CpG) yielded better seroprotective responses than alum-adjuvanted hepatitis B vaccine (HepB-alum) in people with well-controlled HIV. Now, in a follow-up study, investigators evaluated the durability of this seroprotection.
A total of 561 people with HIV who had previously not responded to hepatitis B vaccination were randomized to receive two or three doses of HepB-CpG or three doses of HepB-alum. Seroprotective responses (defined as anti-HBs titer ≥10 mIU/mL) at week 72 were 86% (two-dose HepB-CpG), 97% (three-dose HepB-CpG), and 58% (three-dose HepB-alum).
Reviewing Author
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)